STREAMLINE HEALTH SOLUTIONS INC.: Nasdaq/NYSE listing notice — Streamline Health receives Nasdaq bid price deficiency notice; 180 days to regain compliance

STREAMLINE HEALTH SOLUTIONS INC.

Nasdaq notified on Oct 24, 2023 that STRM closing bid price below $1.00 for 30 consecutive business days.
Company has until April 22, 2024 to regain compliance with Bid Price Requirement.
If compliance not met, Company may be eligible for additional 180-day period if other listing requirements are met.
Failure to regain compliance could result in delisting from Nasdaq Capital Market.
Company intends to monitor bid price and consider available options; no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

STREAMLINE HEALTH SOLUTIONS INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 24, 2023, Streamline Health Solutions, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market indicating that the closing bid price of the Company’s common stock, par value $0.01 per share, has been below the minimum bid price of $1.00 per share for the previous 30 consecutive business days, which is required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has provided the Company with 180

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-038524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.